Kynam Capital Management
Kynam Capital Management reported 34 stocks worth $1.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LEGN (10.1%), CLDX (9.1%) and SNDX (8.5%). Compared with Q2 2026, the fund opened new positions in SRZN, XENE and EVMN, added to LEGN, SNDX and COGT, trimmed CLDX, PCVX and VRDN and sold out of INSM and CADL.
Latest filing: what Kynam Capital Management did in Q3 2026
vs Q2 2026Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() LEGN Legend Biotech Corp | $182M | 10.1% | 9.2M | +6.2M (+205%) | 4 of 8 | |
| 2 | ![]() CLDX Celldex Therapeutics Inc | $164M | 9.1% | 5.1M | −257K (−5%) | 8 of 8 | |
| 3 | ![]() SNDX Syndax Pharmaceuticals Inc | $153M | 8.5% | 8.2M | +100K (+1%) | 8 of 8 | |
| 4 | ![]() PCVX Vaxcyte Inc | $148M | 8.2% | 2.6M | −314K (−11%) | 8 of 8 | |
| 5 | ![]() VRDN Viridian Therapeutics Inc | $127M | 7.0% | 6.1M | −306K (−5%) | 8 of 8 | |
| 6 | ![]() COGT Cogent Biosciences Inc | $121M | 6.7% | 3.8M | +125K (+3%) | 8 of 8 | |
| 7 | ![]() TVTX Travere Therapeutics Inc | $118M | 6.5% | 2M | No change | 8 of 8 | |
| 8 | ![]() URGN Urogen Pharma Ltd | $98.9M | 5.5% | 2.4M | No change | 6 of 8 | |
| 9 | ![]() VERA Vera Therapeutics Inc | $96.9M | 5.4% | 3M | +110K (+4%) | 8 of 8 | |
| 10 | ![]() BEAM Beam Therapeutics Inc | $96.2M | 5.3% | 3.9M | +1.1M (+38%) | 8 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Sold out
held in Q2 2026, gone in Q3 2026Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →Kynam Capital Management 13F FAQ
What does Kynam Capital Management own?
Kynam Capital Management reported 34 stocks worth $1.8B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are LEGN (10.1%), CLDX (9.1%) and SNDX (8.5%). The table above lists every position in the filing (the top 10 without an account).
What did Kynam Capital Management buy and sell in Q3 2026?
Compared with Q2 2026: 4 new positions, 8 added to, 6 trimmed and 2 sold out. New positions include SRZN, XENE and EVMN. It sold all of INSM and CADL.
When will Kynam Capital Management file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is Kynam Capital Management's portfolio worth?
The Q3 2026 filing reports $1.8B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.



















